Table 2 Immunophenotype of Adenoid Basal Lesions.

EMA

14

14

100

Peri-luminary cells

9,20

CD10

1

1

100

All

1

ER**

2

1

50

All

1,11

PR**

2

1

50

All

1,11

p16

11

11

100

All

1,3

Bcl-2

2

2

100

Basaloid cells and peri-luminary cells

1,6

CEA

17

12

71

Peri-luminary cells and squamous areas

1,9,11,14,20

CAM5.2*

9

8

89

All

9

Ki-67

7

7

100

2% positive index [6]; Majority of tumor cells positive [11]; 5–50% of basaloid cells positive [8]

6,8,11

MNF116

9

9

100

All

9

CK7

13

7

54

Basaloid cells and peri-luminary cells

2,6,9,11

CK8

4

4

100

Basaloid cells and peri-luminary cells

2,6,11

CK10

1

1

100

Squamous cells

11

CK13

1

1

100

Squamous cells

11

CK14

2

2

100

Basaloid cells [11] and other "scattered cells" [6]

6,11

CK17

1

1

100

Basaloid cells

11

CK18

1

1

100

Basaloid cells and periluminary cells

11

CK19

1

1

100

Basaloid cells and peri-luminary cells

11

CK20

9

1

11

NS

9

AE1/AE3

6

6

100

All

6,20

CK902

5

5

100

All

20

α-SMA

2

0

0

NA

6,11

MSA

9

1

0

Transitional areas between a combined ABC and ACC

9

Laminin

10

1

10

Basement membrane-like material

6,9

Type IV collagen

10

1

10

Basement membrane-like material

6,9

S100

16

3

19

NS

6,9,11,20

CA125

1

0

0

NA

11

P53

6

6

100

NS

11,13

P63

6

6

100

All: reduction of staining in squamous areas and "adenoid" areas

1,8